Immunic (NASDAQ:IMUX) Downgraded by StockNews.com to Sell

StockNews.com cut shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Brookline Capital Management reissued a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th.

Immunic Trading Up 2.4 %

NASDAQ IMUX opened at $1.26 on Friday. The stock’s 50-day moving average price is $1.32 and its two-hundred day moving average price is $1.26. The company has a market cap of $113.50 million, a PE ratio of -0.60 and a beta of 2.07. Immunic has a 1 year low of $0.95 and a 1 year high of $3.11.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.03. Research analysts forecast that Immunic will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently added to or reduced their stakes in IMUX. Innovis Asset Management LLC raised its position in Immunic by 46.3% in the 3rd quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock valued at $401,000 after purchasing an additional 86,217 shares during the last quarter. Acadian Asset Management LLC lifted its position in Immunic by 26.8% during the 3rd quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock worth $1,111,000 after buying an additional 159,973 shares in the last quarter. RTW Investments LP lifted its position in Immunic by 0.9% during the 3rd quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after buying an additional 40,796 shares in the last quarter. Sweet Financial Partners LLC bought a new stake in Immunic during the 4th quarter worth about $45,000. Finally, Gratus Capital LLC increased its position in Immunic by 15.1% in the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after acquiring an additional 254,999 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.